The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.
The US Food and Drug Administration (FDA) has approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for upfront treatment of adults with locally advanced or metastatic ...
Factoring out nucleotide-level mutation biases from antibody language models dramatically improves prediction of functional mutation effects while reducing computational cost by orders of magnitude.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results